Grail has raised $125 million out of a planned $250 million equity financing offering, according to a recently filed Form D notice with the US Securities and Exchange Commission.

IncellDx said recently that that it has signed an agreement with Singapore-based Biolidics to distribute its IncellDx bioINK PD-L1 CTC Core Kit.

Biotia, a startup providing DNA sequencing-based microbial surveillance services and infectious disease diagnostic tests for hospitals, said recently that it has closed a $2.4 million seed financing round.

Invitae recently announced a partnership with BioMarin Pharmaceuticals on a program to expand access to genetic testing for skeletal dysplasias.

Twist Bioscience reported after the close of the market recently that revenues for its fiscal fourth quarter 2019 rose 87 percent year over year.

Cancer drug developer Oncology Pharma said recently that it has signed a letter of intent to acquire at least 50 percent of molecular genomics firm Diagnomics.

Prescient Medicine said this week that it has partnered with Dutch medical research institute Erasmus MC to evaluate its opioid addiction risk technology in a clinical study in the Netherlands.

Horizon Discovery and Mammoth Biosciences announced recently that they will collaborate to develop new CRISPR tools, with the aim of generating new engineered cell lines for the biopharmaceutical industry.

Healthcare artificial intelligence firm Tempus announced earlier this week the acquisition of Akesogen, the owner of a commercial laboratory and provider of genomics and clinical trial precision medicine services.

The National Institutes of Health has renewed funding for the Antibacterial Resistance Leadership Group (ARLG) with up to $102.5 million over seven years.

Thermo Fisher Scientific on Wednesday reported a 6 percent year-over-year increase in its third quarter revenues, driven by growth across most of its business segments.

PerkinElmer reported after the close of the market a 5 percent year-over-year increase in revenues for the third quarter, falling short of the consensus Wall Street estimate.

Illumina reported after the close of the market recently that its third quarter 2019 revenues grew 6 percent year over year.

Danaher recently reported a 4 percent year-over-year increase in its third quarter revenues, which included a 6 percent rise in life sciences segment revenues and an increase in its diagnostics segment of almost 7 percent.

Qiagen reported after the close of the market recently that its third quarter revenues increased 1 percent year over year, missing analysts' consensus estimate.